Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova in Japanese Patients with Hypertriglyceridemia
NCT02463071Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, dyslipidemia, sponsored by AstraZeneca. Started Jun 2015; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemiadyslipidemia
Beyond the preview
Go deeper on NCT02463071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463071.